Navigation Links
Majority of IsoTis Stockholders Vote for Integra Acquisition
Date:10/29/2007

IRVINE, California, October 29 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders re-convened earlier today, IsoTis stockholders have approved the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007.

The acquisition is expected to close shortly, followed by settlement of the acquisition price of US$7.25 in cash per share. Following the merger, shares of IsoTis common stock will cease to be listed on NASDAQ.

About IsoTis

IsoTis is an orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics products are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution.

On August 7, 2007 Integra and IsoTis announced that they have reached a definitive agreement to create a global orthobiologics leader. The combination would create a comprehensive orthobiologics portfolio, one of the largest sales organizations focused on orthobiologics in the US, and multiple cross-selling opportunities. The transaction is subject to certain closing conditions and approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of Integra and Integra will be one of the largest companies in the world focused on advanced technology in orthobiologics.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including those that refer to management's plans and expectations for, among other things, future operations, strategies, prospects, performance and financial condition and IsoTis' proposed acquisition by Integra. Words such as "strategy," "expects," "plans," "anticipates," "believes," "may," "will," "might," "could," "would," "continues," "estimates," "intends," "pursues," "projects," "goals," "targets" or the negative or other variations thereof and other words of similar meaning are intended to identify such forward-looking statements. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such statements are based on the current expectations and projections of the management of IsoTis only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of IsoTis. Actual results could differ materially from current expectations and projections. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. IsoTis undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE IsoTis Inc
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. “Yes, I need Cosmetic surgery” – view of majority wome
2. Majority Of Women Satisfied With Decision To Have Preventive Mastectomy
3. Majority Of Americans Deny That They Are Overweight
4. Majority of Middle Aged People Suffer from - High BP, High Sugar, Pot Belly
5. Majority of Keralites Vote in Favor of HIV Certificate Before Marriage
6. Majority Of People In US Seek Essential Changes In Health Care System
7. Majority Chinese Men Lack Testosterone: Report
8. Majority Of The Flu Vaccine Supply Received
9. Majority Of Doctors Tend To Ignore Milk Allergy Cases In Babies
10. Majority of Padma Awards Go to Doctors from Delhi
11. Harassment in School Affects Majority of Elementary Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates that circa ... in 2016 cited deficiencies in data integrity. The FDA outlines their expectations for quality ... , Presented as part of the Beckman Coulter Life Sciences Virtual Trade Show ...
(Date:8/16/2017)... Bethpage, NY (PRWEB) , ... August 16, 2017 , ... ... Kullen, Long Island’s original family-owned supermarket, has put together suggestions for enjoying the season ... new recipe or activity, everyone in the family can join in on the fun. ...
(Date:8/16/2017)... ... ... Blue Health Intelligence (BHI) announced today that Dr. Alan Spiro ... over 30 years of clinical, healthcare IT, value-based care, and change management experience to ... “I am thrilled to welcome Dr. Spiro to BHI,” said Swati Abbott, CEO of ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Greenfield Advisors ... companies in the U.S. for the second year in a row. The Inc. 5000 ... past three years. , “To be on the list once is a great accomplishment, ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/27/2017)... 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... the second-quarter 2017 and updated financial guidance for the ... 2017 Highlights Reported net sales of ... prior-year quarter. Net sales at constant currency (organic) grew ... was $0.51, compared to $0.60 in the prior-year quarter. ...
Breaking Medicine Technology: